TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: glenoid radiolucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of confirmed dengue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gastric transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Small-bowel transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completion rate of capsule endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pinch strength of the right hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire parameters
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of a wound complication
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of soy isoflavones
Endpoint domain: Adverse events/effects
Primary endpoint: increase in serum HBV DNA
Endpoint domain: Adverse events/effects
Primary endpoint: exacerbation of viral hepatitis B
Endpoint domain: Adverse events/effects
Primary endpoint: Parenchymal and vascular enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative rate of any bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Asymptomatic status at two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriological eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of insulin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of glucose ≥100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 h UPQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression of renal functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete elimination of aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good neurological outcomes (Glasgow Outcome Scale score 5 or 4)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: bleeding index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial brain oxygenation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficiency of work and mental stability (Schulte test)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of patients reaching target serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20% response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function measured by FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morning adrenaline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalized RV mass (RVM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RV volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone Mineral Density (BMD) of the total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum bone‐specific alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle soreness perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total protein changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological injury score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood transfusions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: epistemic beliefs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: epistemic curiosity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of CD14+HLA-DR+ cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of TLR-2 on CD14+HLA-DR+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNF-α secretion from PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cervical intraepithelial neoplasia‐2 (CIN2) or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative cytology, colposcopy and HPV tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HPV positivity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: in-stent % area loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % NH obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of feeling the exhalent
Endpoint domain: Adverse events/effects
Primary endpoint: Contamination by blood or secretions
Endpoint domain: Adverse events/effects
Primary endpoint: Visual conditions of the surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complement activation products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin levels (IL-1beta, TNF-alpha, IL-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decline in ADL function by hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decline in IADLs three months after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near-maximal inhibition of brain MAO-B enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tramadol requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cough during extubation
Endpoint domain: Adverse events/effects
Primary endpoint: Bruggemann comfort scale (BCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White blood cell changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: treatment outcome rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Puff number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nicotine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in the treatment/management of cardiovascular risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of non-compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response rate on YMRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on CDRS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving competence to practise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of death, postprocedural MI, non-Q-wave MI, or urgent target-lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Composite of death or MI
Endpoint domain: Mortality/survival
Primary endpoint: Composite rate of death, MI, or target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: 4-month poor outcome rate
Endpoint domain: Mortality/survival
Primary endpoint: Maximal flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular itching scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palpebral conjunctival hyperemia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident dementia within 1-3 years of follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Need for oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early contact between participants and BFPCs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Heavy menstrual bleeding (HMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypomenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β-cell function (C-peptide response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: less functional dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less dependence in instrumental activities of daily living
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 10-year Relapse-Free Survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: 10-year Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Seizure-free status postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: tuberculosis treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: weekly levels of social anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure-sensitive areas of the TMJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle/joint pain reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Growth of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Arterial Pressure (MAP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: children's development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Management of depression and BPSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of nonmelanoma skin cancer
Endpoint domain: Mortality/survival
Primary endpoint: Slow-wave sleep (stages 3 and 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stage 1 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defibrillation thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major cardiovascular and cerebrovascular events at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Stent thrombosis within 30 days after primary PCI
Endpoint domain: Adverse events/effects
Primary endpoint: Left Ventricular Stroke Work (LVSW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Length of stay in the intensive care unit (ICU)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: PD20 FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dose response slope (DRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recovery slope (RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of successful intercourse attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of exceeding IOM guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean inspired sevoflurane concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SPC (sevoflurane plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative dose of noradrenaline administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laryngoscopic view quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection drug use (IDU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: SOD and GPx enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBARS and TAS concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average DNA migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of SPECT and PET studies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting Lp(a) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid concentrations
Primary endpoint: Postprandial triglyceride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid concentrations
Primary endpoint: Fasting hsCRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreasing youths' externalizing symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving family functioning
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: improving school attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: running distance in the Yo‐Yo IR1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: penalty time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shot speed and accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of interest and pleasure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: socialization skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Waist-to-Hip Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diameters of IMA and distal RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: NE-induced maximum contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sensitivity of IMA segments to NE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Development of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prostate specific antigen values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurable disease responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable IgG antibody to PT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean concentration of IgG PT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of adverse symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Interference with normal daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Preference for wireless test over catheter-based test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Partial response (PR) in colon cancer cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Longer survival period in colorectal cancer patients
Endpoint domain: Mortality/survival
Primary endpoint: Transitory hypotension as a side effect
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of aggressiveness of weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient intolerance during weaning
Endpoint domain: Adverse events/effects
Primary endpoint: exclusive breastfeeding promotion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SMH recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of fluoride uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pain related brain potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of MDI test to diagnose BHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recovery in the cognitive domain of the PostopQRS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall quality of recovery as measured by the PostopQRS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee-related self-efficacy at 6 years
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal concentrations of levobupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximal concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas under the drug concentration/time curve (AUC(10‐60))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accrual of older patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: postoperative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulpal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IIEF-5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rTNSS (reflective Total Nasal Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANS (Patient-reported Allergic Nasal Symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores at rest and deep breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammation-related signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion area in enamel tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion progression in root tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical items measured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of gE‐specific CD4(+) T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum anti‐gE antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reversal of graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TnT concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to first severe exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first URI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: six-min walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YMRS response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YMRS total score < or = 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YMRS < or = 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distressful sexual dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deviation from recommended doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deviation from recommended equipment sizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking abstinence before delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking rates postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of angina attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall bacterial eradication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed effectiveness rates for AECB and AP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes